[
  {
    "ts": null,
    "headline": "UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma […]",
    "url": "https://finnhub.io/api/news?id=65d9bad19dd473e47c543caab52e21d6607303852b8e0aef9ead0c445a32aa35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769707456,
      "headline": "UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves",
      "id": 138297214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds. On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma […]",
      "url": "https://finnhub.io/api/news?id=65d9bad19dd473e47c543caab52e21d6607303852b8e0aef9ead0c445a32aa35"
    }
  },
  {
    "ts": null,
    "headline": "Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics",
    "summary": "Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finnhub.io/api/news?id=4a5930aaf1463386ffd91a2cabf566f24f505c5783868b3f5d11830bbb991d18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769696104,
      "headline": "Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics",
      "id": 138295685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
      "url": "https://finnhub.io/api/news?id=4a5930aaf1463386ffd91a2cabf566f24f505c5783868b3f5d11830bbb991d18"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
    "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
    "url": "https://finnhub.io/api/news?id=ac20cc2a185006299e808d3584f961830004981752c7cdf3f465ccacace252c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769651400,
      "headline": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
      "id": 138291032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
      "url": "https://finnhub.io/api/news?id=ac20cc2a185006299e808d3584f961830004981752c7cdf3f465ccacace252c4"
    }
  }
]